Related Experiment Video
Updated: Mar 29, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer
Xiaoming Song1, Chunhai Fu2, Xudong Yang1
1Department of Thoracic Surgery, Shandong Qianfoshan Hospital, Jinan, Shandong 250014, P.R. China.
Abstract:
Tripartite motif-containing 29 (TRIM29) is a member of the tripartite motif (TRIM) protein family. TRIM29 has been reported to be deregulated in a number of cancer types, suggesting the oncogenic function of TRIM29. However, its clinical significance in non-small cell lung cancer (NSCLC) has not been fully elucidated. In the present study, the TRIM29 expression status was investigated by immunohistochemical analysis in paraffin-embedded specimens obtained from 320 patients with surgically resected NSCLC, treated between 2000 and 2007. High TRIM29 expression was significantly associated with smoking (P=0.012), T stage (P=0.015) and M stage (P=0.003). Furthermore, elevated TRIM29 expression level was correlated with reduced overall (OS) and disease-free survival. In addition, high TRIM29 expression was an independent prognostic factor for OS [P=0.003, hazard ratio (HR)=2.102, 95% confidence interval (CI), 1.069-3.193]. In conclusion, these results suggest that TRIM29 may be a useful prognostic marker in NSCLC patients and a potential molecular target for NSCLC treatment.
Insights
High expression of Tripartite Motif-Containing 29 (TRIM29) protein correlates with poorer survival in non-small cell lung cancer (NSCLC). TRIM29 may serve as a prognostic marker and therapeutic target for NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Tripartite motif-containing 29 (TRIM29) is implicated in various cancers, but its role in non-small cell lung cancer (NSCLC) remains unclear.
- Understanding TRIM29's clinical significance is crucial for developing targeted therapies and improving patient outcomes in NSCLC.
Purpose of the Study:
- To investigate the expression status of TRIM29 in NSCLC.
- To evaluate the association between TRIM29 expression and clinical characteristics.
- To determine the prognostic value of TRIM29 in NSCLC patients.
Main Methods:
- Immunohistochemical analysis of TRIM29 expression in 320 surgically resected NSCLC specimens.
- Statistical analysis to correlate TRIM29 levels with clinicopathological factors and survival outcomes.
- Prognostic analysis using overall survival (OS) and disease-free survival (DFS) data.
Main Results:
- High TRIM29 expression was significantly associated with smoking history, T stage, and M stage in NSCLC patients.
- Elevated TRIM29 levels correlated with reduced overall survival (OS) and disease-free survival (DFS).
- High TRIM29 expression emerged as an independent prognostic factor for OS (P=0.003, HR=2.102).
Conclusions:
- TRIM29 expression is a significant prognostic indicator in NSCLC.
- TRIM29 may be a valuable biomarker for predicting patient survival.
- TRIM29 represents a potential molecular target for novel NSCLC treatments.
More Related Videos
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
08:49Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
